Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AZD4831 in Severe Renal Impairment
NCT04949438Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mitiperstat in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by AstraZeneca. Primary endpoints: Maximum observed plasma concentration, Time to reach maximum observed plasma concentration and 7 more. Started Jan 2022; status: completed.
02
Drugs
mitiperstat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04949438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04949438.